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Abstract
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γ -Aminobutyric acid (GABA) is the major inhibitory neurotransmitter in the central nervous
system. Inhibition of GABA aminotransferase (GABA-AT), a pyridoxal 5′-phosphate (PLP)dependent enzyme that degrades GABA, has been established as a possible strategy for the
treatment of substance abuse. The raised GABA levels that occur as a consequence of this
inhibition have been found to antagonize the rapid release of dopamine in the ventral striatum
(nucleus accumbens) that follows an acute challenge by an addictive substance. In addition,
increased GABA levels are also known to elicit an anticonvulsant effect in patients with epilepsy.
We previously designed the mechanism-based inactivator (1S,3S)-3-amino-4difluoromethylenyl-1-cyclopentanoic acid (2), now called CPP-115, that is 186 times more
efficient in inactivating GABA-AT than vigabatrin, the only FDA-approved drug that is an
inactivator of GABA-AT. CPP-115 was found to have high therapeutic potential for the treatment
of cocaine addiction and for a variety of epilepsies, has successfully completed a Phase I safety
clinical trial, and was found to be effective in the treatment of infantile spasms (West syndrome).
Herein we report the design, using molecular dynamics simulations, synthesis, and biological
evaluation of a new mechanism-based inactivator, (S)-3-amino-4-(difluoromethylenyl)cyclopent-1*
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ene-1-carboxylic acid (5), which was found to be almost 10 times more efficient as an inactivator
of GABA-AT than CPP-115. We also present the unexpected crystal structure of 5 bound to
GABA-AT, as well as computational analyses used to assist the structure elucidation process.
Furthermore, 5 was found to have favorable pharmacokinetic properties and low off-target
activities. In vivo studies in freely moving rats showed that 5 was dramatically superior to
CPP-115 in suppressing the release of dopamine in the corpus striatum, which occurs subsequent
to either an acute cocaine or nicotine challenge. Compound 5 also attenuated increased metabolic
demands (neuronal glucose metabolism) in the hippocampus, a brain region that encodes spatial
information concerning the environment in which an animal receives a reinforcing or aversive
drug. This multidisciplinary computational design to preclinical efficacy approach should be
applicable to the design and improvement of mechanism-based inhibitors of other enzymes whose
crystal structures and inactivation mechanisms are known.

Author Manuscript

Graphical Abstract

INTRODUCTION
Author Manuscript

γ-Aminobutyric acid (GABA) is the major inhibitory neurotransmitter in the central nervous
system of mammals.1 After its release from presynaptic inhibitory neurons, it can bind to
chloride-selective ion channel receptors (GABAA and GABAC)2 and G-protein coupled
receptors (GABAB)3 to hyperpolarize the postsynaptic membrane, thereby downwardly
controlling neuronal activity. 4 Low levels of GABA are linked to many neurological
disorders, including epilepsy,5 Parkinson’s disease,6 Alzheimer’s disease,7 and Huntington’s
disease.8

Author Manuscript

In 1998 a novel strategy was developed for the treatment of cocaine addiction based on
inhibiting the activity of γ-aminobutyric acid aminotransferase (GABA-AT), 9 the pyridoxal
5′-phosphate (PLP)-dependent enzyme that degrades GABA to succinic semialdehyde via
an aldimine intermediate (1, Scheme 1). GABA-AT inhibition raises GABA levels, which
antagonizes the rapid release of dopamine in the nucleus accumbens (NAcc) that occurs as a
neurochemical response to cocaine or other drugs of abuse.9 Since then, the anti-epilepsy
drug vigabatrin, the only FDA-approved drug that acts as an inactivator of GABA-AT,10 has
been successful in the treatment of addiction in animal models for cocaine,9 nicotine,11
methamphetamine, heroin, and alcohol.12 Vigabatrin also was effective in the treatment of
cocaine addiction in humans,13,14 with up to 28% of patients achieving abstinence in a 9week double-blind trial.15 The therapeutic potential of vigabatrin as a treatment for

J Am Chem Soc. Author manuscript; available in PMC 2019 February 14.

Juncosa et al.

Page 3

Author Manuscript

addiction, however, may be problematic because permanent retinal damage has been
reported in 25–40% of patients after long-term administration.16

Author Manuscript

In an effort to minimize or eliminate this side effect, we designed a mechanism-based
inactivator,17 (1S,3S)-3-amino-4-difluoromethylenyl-1-cyclopentanoic acid (2, Scheme 2),
now called CPP-115, which is 186 times more efficient in inactivating GABA-AT than
vigabatrin.18 A mechanism-based inactivator is an unreactive compound that requires target
enzyme catalysis to convert it to a species that inactivates the enzyme prior to that species
leaving the active site. When tested in a multiple-hit rat model of infantile spasms, CPP-115
suppressed spasms at doses over 100-fold lower than those used for vigabatrin and
additionally produced longer spasm suppression.19 This compound also was more effective
against addictive challenges; when tested in freely moving rats after administration of 20
mg/kg cocaine, CPP-115 was over 300 times more potent than vigabatrin in reducing the
release of dopamine in the NAcc.20 Administration of CPP-115 (1 mg/kg) with cocaine
given to cocaine-addicted rats showed a similar effect in eliminating their addictive behavior
as with administration of vigabatrin at 300 mg/kg with cocaine. CPP-115 also displayed a
much larger margin of safety and a considerably lower retinal toxicity liability than
vigabatrin.19 To date, CPP-115 has completed a Phase I safety clinical trial without adverse
effects. In addition, a child with infantile spasms refractory to all treatments has been treated
successfully with CPP-115.21

Author Manuscript
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Originally, CPP-115 was designed to inactivate GABA-AT via a Michael addition
mechanism that would lead to a covalent adduct with the enzyme, similar to that with
vigabatrin.18 However, it was discovered from the crystal structure of GABA-AT inactivated
by CPP-115 that the enzyme forms a noncovalent, tightly-bound complex with CPP-115 via
strong electrostatic interactions between the two carboxylate groups in the resulting
metabolite with Arg192 and Arg445 in the active site (Scheme 2).22 Inactivation is initiated
by Schiff base formation between CPP-115 and the lysine-bound PLP, followed by γ-proton
removal and tautomerization, resulting in a highly reactive Michael acceptor (3, Scheme 2).
However, before Lys329 can attack this Michael acceptor, catalytic hydrolysis of the
difluoromethylenyl group occurs, leading to the PLP-bound dicarboxylate metabolite (4,
Scheme 2), which elicits a conformational change in the enzyme and tightly binds to Arg192
and Arg445 via electrostatic interactions. Molecular dynamic simulations and computer
modeling indicated a movement of the difluoromethylenyl group of CPP-115 away from
Lys329 upon enzyme-catalyzed tautomerization, leaving it too far away from Lys329 for
nucleophilic attack; the enzyme catalyzes its hydrolysis instead.22 On the basis of further
classical molecular dynamics simulations and computer modeling with GABA-AT, we have
identified a design approach that would bring the electrophilic intermediate closer to Lys329
for the encouragement of nucleophilic addition and covalent bond formation. This approach,
the unexpected outcome, and the in vitro and in vivo properties of the designed molecule are
reported here.
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RESULTS AND DISCUSSION
Design of a highly potent GABA-AT inactivator
To avoid or minimize the movement of the difluoromethylenyl group away from Lys329
after tautomerization, we proposed to minimize the flexibility of the ring by incorporating a
double bond into the structure of CPP-115, leading to the design of the mechanism-based
inactivator (S)-3-amino-4-(difluoromethylenyl)cyclopent-1-ene-1-carboxylic acid (5, Figure
1). Flexible docking followed by classical molecular dynamic simulations of the
tautomerized form of 5 within the active site of GABA-AT showed that the incorporation of
the endocyclic double bond left the difluoromethylenyl group closer to the Lys329 nitrogen
atom (4.6 ± 0.3 A) than in the case of CPP-115 (7.5 ± 0.6 A) (Figure 2). The visualization
provided by these molecular dynamics simulation studies provided validation to synthesize
and test 5.

Author Manuscript
Author Manuscript

To eliminate differences in ring dynamics as a reason for the shorter CF2-Lys329 distances,
Principal Component Analyses (PCA) of the ring carbons’ motions during the last 40 ns of
the simulations were performed for both CPP-115 and 5. These multivariate analyses
highlight the major multiatom conformational changes from other main molecular motions
within a MD trajectory. Even though 5 was determined to be noticeably more rigid, the
analyses ultimately suggested there were similar dynamic modes associated with the fivemembered rings of both CPP-115 and 5; therefore, dynamics of the five-membered rings
cannot be the reason for the different distances from Lys329 (see Supporting Information
Figures S1 and S2). Figure 3A shows the projection of trajectories on the common subspace
defined by the top two Principal Components (PC1 and PC2) for the two inhibitors in the
tautomerized complexes. The larger overlap between CPP-115 and 5 in both complexes is
evidence for the similar conformational space shared by both inhibitors in the complexes.

Author Manuscript

On the other hand, we found that the average structures corresponding to the energy
minimum of the free energy landscape of CPP-115 and 5 (along PC1 and PC2) in the
tautomerized complex reveal an envelope conformation for CPP-115 and a more planar
conformation for 5 (Figure 3B). Visual inspection of the trajectories also confirms the
presence of these two average structures. Interestingly, the PCA using the entire trajectory
(50 ns) reveals two well separated clusters for CPP-115, which identifies a movement of the
equatorial carboxylate group of CPP-115 to an axial carboxylate around 4 ns, where the
significant Lys329-CF2 distance difference starts to appear (Figure 2A and Supporting
Information Figures S1 and S2). Density Functional Theory (DFT) calculations of the
optimized structures (B3LYP/6-311++G(d, p)) corresponding to the isolated conformations
with axial and equatorial carboxylate groups in implicit water indicate a 0.075 kcal/mol
slight stability in favor of the axial conformation, which is also the more prominent form in
the enzyme active site (Supporting Information Figure S3; for detailed procedure, see
Supporting Information). This change in relative orientation between the carboxylate and
amino pharmacophoric groups in the CPP-115 tautomer causes a realignment of the
molecule within the binding site to accommodate the interaction of the carboxylate with
Arg192, which pulls the difluoromethylene group away from Lys329. In the case of 5, the
endocyclic double bond prevents the ring from adopting an envelope conformation because
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of geometric constraints, which prevents any major conformational changes between the
original and tautomerized versions of the molecule. This major conformational difference
between CPP-115 and 5 explains the Lys329-inhibitor distance difference, in which the
difluoromethenyl group in 5 is closer to the catalytic Lys329 than that in CPP-115 (Figure 2
and Supporting Information Figure S4).
Even though these computational studies encompass only geometric factors, and not
electronic ones like pKa changes that might impact reaction rates, the calculations suggest
that 5 would be more likely than CPP-115 to inactivate GABA-AT by a covalent
mechanism; consequently, a synthesis for 5 was devised.
Synthesis of 5

Author Manuscript

The synthesis of 5, shown in Scheme 3, started from CPP-115 (2).18 The carboxylic acid
and amino groups were protected (6), and then the α-carbon was selenated, resulting in a 7:3
inseparable mixture of diastereomeric selenides (7). The protecting groups were removed to
afford 9; it was found that the purity of 9 was crucial for the final purity of 5. Oxidative
elimination of the phenylselenyl group in 9 under mild conditions gave a 5:3 isomeric
mixture of 5 and 10. Many attempts to separate 5 from 10 by chromatography were
unsuccessful, but it was discovered in the process that 10 was much more reactive than 5.
Consequently, a strategy involving selective modification and removal of more reactive 10
using a soft thiol nucleophile (2-mecaptobenzoic acid) was successfully developed.
In vitro activity of 5

Author Manuscript
Author Manuscript

In vitro studies showed that 5 was an exceedingly potent inactivator of GABA-AT. In fact,
the inactivation occurred so rapidly that the inhibition constant (KI) and the rate constant of
enzyme inactivation (kinact) for the inactivation of GABA-AT by 5 could not be determined
accurately using a Kitz and Wilson replot,23 even under nonoptimal conditions that were
originally done by Pan et al. for CPP-115.18 A recently developed progress curve analysis
method24 was then used to measure the kinetic constants (Supporting Information Figure
S5), which allowed us to perform the measurements under optimal conditions. This same
method was used to measure the kinetic constants of 4-amino-5-fluoropentanoic acid,
vigabatrin, and CPP-115, and we compared the results with those obtained previously using
the Kitz and Wilson procedure, as a means to validate this new approach (Supporting
Information Figure S6). The results showed that 5 had a higher binding affinity to GABAAT than CPP-115 (KI values of 5 and CPP-115 were 9.69 ± 1.50 μM and 58.8 ± 6.9 μM,
respectively), and 5 also inactivated GABA-AT with a larger rate constant than CPP-115
(kinact values of 5 and CPP-115 were 3.32 ± 0.23 min−1 and 2.05 ± 0.09 min−1,
respectively). Overall, the efficiency constant for 5 (kinact/KI = 342 ± 58 mM−1min−1) is 9.8
times larger than that for CPP-115 (kinact/KI = 34.9 ± 4.4 mM−1min−1); therefore, 5 is 9.8
times more efficient as an inactivator of GABA-AT than CPP-115!
Because 5 was designed to act by irreversible (covalent) inhibition, time-dependent
reactivation of GABA-AT after treatment with the compound was conducted to test if the
mechanism involved both irreversible and reversible components, as was observed for
CPP-115.22 After GABA-AT activity was completely abolished by 10–1000 equivalents of 5
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with 4 h incubation, the treated enzyme was dialyzed, and aliquots at different time intervals
(7, 24, and 48 h) were collected and assayed for return of enzyme activity. At 10, 40, and
100 equivalents of 5, activity returned to 30%, 25%, and 15%, respectively, after 24 h of
dialysis, and these values remained the same at 48 h (Figure 4, Left). With 1000 equivalents
of 5, no enzyme activity returned, even after 48 h of dialysis. In comparison with CPP-115,
the same experiment gave approximately the same results. The return of a small amount of
enzyme activity from 5- and CPP-115-inactivated GABA-AT at lower concentrations of
inactivators indicates that the inactivation includes both an irreversible and a reversible
component, as was the case for CPP-115.22 Additionally, the turnover number (the
extrapolated number of molecules needed to inactivate the enzyme fully) for 5 was found to
be 1.08 ± 0.08 compared to a value of 1.03 ± 0.01 for CPP-115, and 5 demonstrated
nonpseudo-first order kinetics, as was previously observed with CPP-115,21 also suggesting
both irreversible and reversible components of inactivation (Figure 4, right). The similarities
in percent reactivation and turnover number of the two molecules indicate that the increase
in activity of 5 does not arise from more efficient turnover by the enzyme.
Crystal structure of 5 bound to GABA-AT

Author Manuscript

To gain a better understanding of the mechanism of inactivation of GABA-AT by 5, we
obtained an X-ray crystal structure of the inactivated enzyme, refined to a resolution of 1.95
A in space group P1211; the final Rwork/Rfree values were 0.169/0.215, respectively
(Supporting Information Table S2). Unexpectedly, the refined models showed, as in the case
of CPP-115,22 a noncovalent, tight-binding inhibitor complex where the difluoromethylene
group has been hydrolyzed to a carboxylate (Figure 5; see Figure S7 in Supporting
Information for the simulated annealing omit map (Fo−Fc) around the ligand moiety (5) at
2.5 μ and the refined 2Fo−Fc map around the final adduct at 1.0 μ). On the basis of our
computer model (Figure 2B), which showed that the electrophilic difluoromethylenyl group
of 5 after tautomerization was closer to Lys329 than that of CPP-115 after tautomerization
(4.6 A for 5 and 7.5 A for CPP-115), we thought a covalent reaction with Lys329 would
occur, as was seen when vigabatrin inactivated GABA-AT,25 but there was no evidence of
this in the crystal structure model. Apparently, 4.6 A is still too far from Lys329 for
nucleophilic attack.
Effect of active site water molecules

Author Manuscript

To rationalize a hydrolysis mechanism, we considered the case of aspartate aminotransferase
with substrate and substrate analogues,26 for which the active-site lysine (Lys258 in AspAT) has been proposed to be the base that deprotonates a water molecule and catalyzes
hydrolysis of the tautomerized aldimine intermediate. For GABA-AT this would correspond
to hydrolysis of 1 from GABA (B = Lys329 in Scheme 1) on the way to succinic
semialdehyde and, by analogy, hydrolysis of intermediate 3 from CPP-115 (B = Lys329 in
Scheme 2) leading to inactivated enzyme (4). This hydrolysis mechanism in GABA-AT is
supported by the distribution of water molecules around the ε-nitrogen atom of Lys329 in
the tautomerized CPP-115 complex, as observed by classical MD simulations. A comparison
of the radial distribution function of water molecules around the Lys329 nitrogen with that
for adjacent Lys330 and a surface lysine residue (Lys207) demonstrates that Lys329 has a
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close, well-ordered hydration sphere (1.8 A) followed by two less ordered hydrogen spheres
around 2.9 A and 3.2 A, respectively (Figure 6). By comparison, neither Lys330 nor Lys207
has a close well-ordered hydration sphere, indicating a higher probability that Lys329 can
induce a water-mediated nucleophilic attack. A similar result was seen for the radial
distribution function of 5 in the tautomerized complex. Therefore, having the electrophilic
difluoromethylenyl group closer to Lys329 also puts it closer to the catalytic water molecule,
which enhances the hydrolysis of the difluoromethylenyl group and increases the efficiency
of inactivation with 5, as shown in the MD simulation result (Figure 2).
Tautomeric forms of the structure of 5-inactivated GABA-AT

Author Manuscript
Author Manuscript

On the basis of the crystal structure in Figure 5 and the in vitro activity (Figure 4), the
mechanism of inactivation of GABA-AT by 5 closely resembles that by CPP-115 (Scheme
2). However, the structure of 5-inactivated GABA-AT theoretically could be any one (or
more than one) of eight tautomeric forms (Figure 7). Although identification of the structure
of the bound tautomeric form does not shed any more light on the inactivation mechanism, it
presents an interesting challenge, which we attempted to resolve by various computational
methods. The electron density of the crystal structure of 5 bound to GABA-AT (Supporting
Information Figure S7B) reveals that the ring has an sp3 carbon atom adjacent to the
carboxylate that was initially the difluoromethylenyl group. Of the eight theoretical
tautomeric forms of the enzyme-bound inactivator-PMP structure (11a–h, Figure 7), only
three of them would accommodate an sp3 atom in the ring at that position (11a–c). On the
basis of the crystal structure (Figure 5 and Supporting Information Figure S7), it is not
possible to differentiate these three tautomeric forms. Consequently, we performed DFT
calculations with a large B3LYP/6-311++G(d,2p) basis set on interaction models of each
tautomer with residues within a 5 A radius according to their X-ray crystallographic
distances to determine their interaction energies (Supporting Information Figure S8; see
details in Supporting Information). Basis set superimposition error-corrected gas phase
interaction energies for the models of tautomers 11a–c at each nearby residue are shown in
Table 1. The DFT calculations show that the tautomer with the lowest interaction energies is
11c.

Author Manuscript

The difference in the total interaction energy between 11a and 11c is 4.71 kcal/mol, but the
difference in interaction energy from the interaction with Arg192 alone is 5.36 kcal/mol. To
determine if the stabilization energy from the Arg192 interaction, resulting from electron
delocalization and hyperconjugation, accounts for the difference in the total interaction
energy of tautomer 11a vs 11c, natural bond orbital (NBO) analysis was carried out. NBO
analysis, which provides information about the interactions between the filled (bonding or
lone pair) Lewis type NBOs (donor) and the empty (antibonding or Rydberg) non-Lewis
NBOs (acceptor) (Supporting Information Figure S9; see Supporting Information for
details), shows a difference of 4.84 kcal/mol in their stabilization energies in favor of 11c,
supporting the importance of the enhanced interaction of 11c with Arg192 in stabilizing the
entire tautomer complex. These calculations do not take into account the kinetics for the
formation of 11a–c, which is beyond the scope of this work. The exact identity of the final
metabolite tautomer, whether 11a or 11c, does not affect the overall mechanistic result,
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namely, that 5 inactivates GABA-AT in a manner similar to CPP-115, except that
tautomerization to a more stable complex can occur.

Author Manuscript

As a result of inactivation, the catalytic lysine (Lys329) is freed from its covalent linkage to
the PLP, and the final adduct forms salt bridges with Arg445 and Arg192 (Figure 5). Gln301
also is within hydrogen bonding distance to the newly formed carboxylate of the inactivated
enzyme adduct. Glu270, which forms a salt bridge with Arg445 in the native structure, has
been displaced by the newly formed carboxylate of the inactivated enzyme adduct. In all of
the tautomer cases, Glu270 has highly repulsive interactions (11a = 117.26 kcal/mol, 11b =
119.29 kcal/mol, 11c = 116.88 kcal/mol) because of its proximity to the new negatively
charge carboxylate group of the tautomers. On the basis of this information, we suggest that
the two strong salt bridge interactions between the ligand and the arginine residues (Arg192
and Arg445) overcome this repulsive interaction. These calculations also explain how the
ligand is capable of replacing the native Arg445-Glu270 salt-bridge interaction with newly
formed salt bridge interactions between the ligand and the two arginine residues.
Potential off-target activity and favorable ADMET profile of 5

Author Manuscript

Unlike vigabatrin,27 CPP-115 was reported not to inactivate or inhibit off-target enzymes,
such as aspartate aminotransferase (Asp-AT) and alanine aminotransferase (Ala-AT),22
which could have contributed to its larger margin of safety than vigabatrin. Therefore, the
activity of 5 was also tested with these off-target enzymes. The results showed that 5 also
does not cause time-dependent inhibition and is only a very weak reversible inhibitor of both
Asp-AT and Ala-AT with an IC50 > 4 mM (Supporting Information Figures S10 and S11,
respectively). Another important PLP-dependent off-target enzyme is ornithine
aminotransferase (OAT).28 CPP-115 was reported to be a moderate inactivator of OAT with
a KI value of 0.116 mM and a kinact value of 0.097 min−1.29 Therefore, compound 5 also
was tested for activity against OAT; the results showed that 5 is a potent inactivator of OAT
with a KI value of 0.0033 mM and a kinact value of 0.025 min−1 (Supporting Information
Figure S12). A comparison of the kinact/KI value of 5 (7.6 mM−1min−1) with that of
CPP-115 (0.84 mM−1min−1) shows that 5 is 9.0 times more efficient as an inactivator of
OAT than CPP-115, consistent with its 9.8 times higher efficiency as an inactivator of
GABA-AT. Acute inhibition of human OAT has been shown to be beneficial for the
treatment of hepatocellular carcinoma.29 Given that 5 is 44 times more effective at inhibiting
GABA-AT than OAT, and considering that the effective dose of 5 should be quite low, we do
not expect side effects from this inactivation.

Author Manuscript

hERG is a potassium ion channel that contributes to the electrical activity of the heart, which
coordinates the heart’s beating.30 This channel is sensitive to drug binding, and when its
ability to conduct electrical current across the cell membrane is compromised, it can result in
potentially fatal cardiac adverse effects; therefore, it is important to avoid hERG inhibition
during drug development.30 Like CPP-115,22 5 does not inhibit the activity of the hERG
channel, even at 10 μM concentration (Supporting Information Figure S13).
Microsomal cytochromes P450 (CYPs) are major enzymes that are involved in drug
metabolism, accounting for ~ 75% of all drug metabolism.31 Inhibition or activation of
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CYPs can lead to undesirable drug-drug interactions. As with CPP-115,22 5 does not inhibit
or induce the seven most common CYPs (1A, 2B6, 2C8, 2C9, 2C19, 2D6, and 3A) that are
involved in >95% of the reactions in drug metabolism,31 even at 10 μM concentration
(Supporting Information Figure S14). Furthermore, plasma protein binding is only 27%,
indicating a high percentage of free drug in plasma.
Compound 5 was also evaluated for its metabolic stability in human liver microsomes
(HLM) by incubating 5 with microsomes and monitoring its disappearance over time using
LC-MS/MS. Terfenadine was run under the same conditions as a positive control. No
metabolism of 5 was observed over the 90 min assay time.

Author Manuscript

To determine if 5 affects other important pharmacological targets, the Cerep
SpectrumScreen (Eurofins/Cerep Panlabs) of 176 pharmacological targets showed no
significant activity with any of the targets at 3 μM concentration. It also was negative in the
Ames test for mutagenicity (Eurofins/Cerep Panlabs), and, on the basis of the Irwin (primary
observation) test (Porsolt) in mice, the no observed adverse effect level (NOAEL) was 6
mg/kg by oral administration.
Effect of 5 on cocaine and nicotine addiction in rats
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Addiction is a consequence of the release of dopamine in the NAcc when an addictive
substance is ingested or an addictive behavior occurs. The effect of 5 on the release of
dopamine at the NAcc in freely moving rats was determined using in vivo micropositron
emission tomography (microPET) imaging (Figure 8).9 In the central nervous system,
especially the corpus striatum, there is a high concentration of dopamine D2 receptors, as
seen by the red in each image in Figure 8, which corresponds to [11C]-raclopride binding;
[11C]-raclopride competes with dopamine for the same receptor sites located on postsynaptic
dopamine terminals. MicroPET was used to measure the dissociation of the [11C]-raclopride
tracer from dopamine receptors caused by either cocaine- or nicotine-induced increases in
synaptic dopamine levels. When animals received cocaine (n = 8) or nicotine (n = 6), the
striatal dopamine levels rapidly increased;32 these elevations effectively displaced [11C]raclopride from the receptors, as seen in Figure 8 (middle frame; the intensity of the red is
much lower). If the same animals (on a different day) received 5 (1.0 mg/kg) prior to
cocaine or nicotine, there was no significant change in [11C]-raclopride binding (Figure 8,
bottom frame); the degree of redness is equal to that of the controls (Figure 8, top frame),
indicating that there was no increase in dopamine levels that would effectively compete with
[11C]-raclopride binding. Therefore, 5 blocks both cocaine- and nicotine-induced elevations
of dopamine, thereby blocking the addictive reward response. These experiments were
carried out at three low doses of 5, 1.0 mg/kg, 0.1 mg/kg, and 0.01 mg/kg. The results in
Table 2 indicate that a 10 mg/kg dose of cocaine reduces [11C]-raclopride binding by 36%,
which represents an increase in dopamine release. A 0.01 mg/kg dose of 5 administered 30
minutes prior to cocaine reduced [11C]-raclopride binding by 20%, 0.1 mg/kg dose of 5
reduced [11C]-raclopride binding by 12%, and 1.0 mg/kg dose of 5 reduced [11C]-raclopride
binding by 5% (comparable to control). CPP-115 was shown earlier to be 300–600 times
more potent in inhibiting cocaine-induced dopamine release than vigabatrin; a 0.5 mg/kg
dose of CPP-115 was comparable to a 300 mg/kg dose of vigabatrin.20 We have now shown
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that, in vitro, 5 is 9.8 times more potent than CPP-115 and inhibits dopamine release at a
dose of 0.01 mg/kg following a cocaine challenge. Compound 5 is the most potent
compound we have tested to date for antiaddictive properties. If this potency translates to
humans, it would mean therapeutic doses in the very low milligram range, which would have
the benefit of low liability potential from idiosyncratic toxicity.33
Effect of 5 on rat brain hippocampus glucose metabolism

Author Manuscript
Author Manuscript

[18F]-2′-Fluoro-2′-deoxy-D-glucose (18FDG) and microPET were used to examine the
regional effects of 5 on cocaine-induced increases in glucose metabolism. 18FDG is an
analogue of glucose that is taken up into neurons (or any cells in the human body) just like
glucose. However, after 18FDG is phosphorylated, the corresponding 6′-phosphate cannot be
further metabolized in the glycolytic pathway and remains in cells. Consequently, human
PET studies have used 18FDG for decades to map the brain.34 For example, if an individual
in a PET scanner performs a specific task with one hand while 18FDG is injected
intravenously, neurons in the brain underlying that hand’s ability to perform that task
incorporate this radiolabeled sugar while other surrounding neurons do not. When a human
or a rat receives a psychostimulant like cocaine, dopamine floods the synapse, causing
postsynaptic neurons to fire frantically. Because this neuronal firing requires energy in the
form of glucose, the result is that brain glucose metabolism increases in specific brain
regions. The effect of 5 on cocaine-induced increases in glucose metabolism in freely
moving rats was determined using statistical parametric mapping, in which all of the images
from the cocaine-only animals were added together and then compared to the images
obtained from the same animals that received 5 and cocaine. A statistical threshold (p <
0.00001) was set, and a statistical parametric map, an image showing all the pixels that were
statistically different between the two conditions, was generated and then overlaid on an
MRI of the rat brain (Figure 9). In the cocaine-only animals, an enormous activation in the
hippocampus, a bilateral structure, was observed with one large bright red spot on each side
(Figure 9, left). However, in the cocaine/5 animals, no activation in the hippocampus was
detected (Figure 9, right). This is the largest attenuation by ingestion of a compound that we
have ever observed. Vigabatrin and CPP-115 previously went through similar tests; they
both blocked cocaine-induced increases in striatal dopamine but did not completely block
the hippocampal metabolism as 5 did.

Author Manuscript

Cocaine- and nicotine-induced increases in striatal dopamine dose-dependently produce a
conditioned place preference, which results in animals ‘learning’ to associate a specific
environment with the drug they receive, which leads to dopamine release when they return to
that environment, even in the absence of the stimulant. When the striatum is activated by an
elevation in dopamine levels (subsequent to a cocaine or nicotine challenge), projections to
the hippocampi cause it to activate. The hippocampus plays a pivotal role in spatial memory;
therefore, it is important for encoding environmental conditions during drug exposure.
Because 5 blocked cocaine-induced increases in striatal dopamine, it is not surprising that it
also inhibited increased metabolic demands in the hippocampus.
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CONCLUSION
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On the basis of molecular dynamics simulations with CPP-115 (2) bound to GABA-AT and
molecular docking, we have designed an exceedingly potent mechanism-based GABA-AT
inactivator, (S)-3-amino-4-(difluoromethylenyl)cyclopent-1-ene-1-carboxylic acid (5), which
was predicted to have the generated reactive group much nearer to Lys329 for potential
covalent modification, unlike that of CPP-115. Flexible docking alone did not show a
difference in the distance between the difluoromethylenyl group and Lys329 with CPP-115
or 5 bound; the desired difference was observed only after classical molecular dynamics
simulations. In vitro results show that 5 is 9.8 times more efficient as an inactivator of
GABA-AT than CPP-115, previously the most potent GABA-AT inactivator; CPP-115
displays high therapeutic potential as a treatment for addiction and has been found to be
effective in treating infantile spasms.19 The crystal structure, unexpectedly, showed that the
irreversible inhibition of GABA-AT by 5 is the result of a noncovalent, tight-binding
complex, just like CPP-115. The crystal structure electron density map, along with
calculations using density functional theory and natural bond orbital analysis, were used to
elucidate an interesting question, namely, which of the eight possible tautomeric forms of
the adduct is most likely the structure bound to the enzyme in terms of interaction energies..
Given the inability of X-ray crystallography to differentiate tautomeric forms, these
combined computational approaches were able to predict tautomer 11c was most likely the
bound structure. Compound 5 had little off-target activity, with the notable exception of
inactivating OAT, which has been previously shown to be a viable approach to inhibit the
growth of hepatocellular carcinoma.29 In vivo studies in freely moving rats showed that 5 is
superior to CPP-115 and vigabatrin in suppressing the release of dopamine in the NAcc
following a cocaine- or nicotine challenge. Compound 5 also promoted the highest
attenuation we have observed of dopamine-induced increases in metabolic demand within
the hippocampus, a brain region previously demonstrated to encode spatial conditions of the
environment (conditioned place preference) associated with drug-induced increases in
dopamine. The studies described here demonstrate the combined power of mechanistic
enzymology and molecular dynamic simulations with molecular docking to be important in
the design and improvement of mechanism-based inhibitors of enzymes whose crystal
structures and inactivation mechanisms are known.

EXPERIMENTAL SECTION
General Procedures

Author Manuscript

CPP-115 was synthesized at IRIX Pharmaceuticals for Catalyst Pharmaceuticals, which
generously provided it; other chemicals were obtained from Sigma-Aldrich and used as
received unless specified. All syntheses were conducted with anhydrous conditions under an
atmosphere of argon, using flame-dried glassware and employing standard techniques for
handling air-sensitive materials, unless otherwise noted. All solvents were distilled and
stored under an argon or nitrogen atmosphere before use. 1H NMR and 13C NMR spectra
were taken on a Bruker AVANCE III 500 spectrometer, an Agilent DDR2 400 MHz
spectrometer, or an Agilent DD2 500 MHz spectrometer with an Agilent 5 mm HFX probe
at 26 °C using DMSO-d6 or D2O as solvents, recorded in δ (ppm) and referenced to DMSO-
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d6 (2.50 ppm for 1H NMR and 39.52 ppm for 13C NMR) or D2O (4.79 ppm for 1H NMR).
High resolution mass spectra (HRMS) were measured with an Agilent 6210 LC-TOF (ESI,
APCI, APPI) mass spectrometer.
Methyl (1S,3S)-3-((tert-butoxycarbonyl)amino)-4-(difluoromethylenyl)cyclopentane-1carboxylate (6)

Author Manuscript

To dry methanol (27 mL) was added acetyl chloride (2.49 mL, 35 mmol) at 0 °C, and the
mixture was stirred for 10 min. To the resulting solution was added CPP-115 hydrochloride
salt (2, 1.50 g, 7.0 mmol), and stirring continued for 24 h at room temperature.
Triethylamine (6.84 mL, 49 mmol) and di-tert-butyl dicarbonate (1.93 mL, 8.4 mmol) were
then added, and the resulting solution was stirred for 20 h at room temperature. The reaction
mixture was concentrated and redissolved in ethyl acetate. The organic solution was washed
with 2 N HCl, saturated NaHCO3, and brine. The organic layer was dried over Na2SO4,
followed by filtration and evaporation to afford 6 (1.99 g, 6.83 mmol, 97%) as a white solid.;
1H NMR (500 MHz, 60 °C, DMSO-d ) δ 6.89 (s, 1H), 4.57 (s, 1H), 3.63 (s, 3H), 2.86 (m,
6
1H), 2.55–2.51 (m, 1H), 2.23 (ddt, J = 10.0, 7.1, 2.9 Hz, 1H), 1.79 (m, 1H), 1.39 (s, 9H).;
13C NMR (126 MHz, 60 °C, DMSO-d ) δ 173.74, 154.78, 152.80, 150.54, 148.27, 92.12,
6
91.98, 91.84, 77.86, 51.72, 49.45, 40.31, 36.51, 28.31, 28.16.; 19F NMR (470 MHz, 60 °C,
DMSO-d6) δ −89.49 (d, J = 55.9 Hz), −92.89 (d, J = 57.7 Hz).; HRMS (M+Na+) calcd for
C13H19F2NNaO4 314.1174, found 314.1179.
Methyl (3S)-3-((tert-butoxycarbonyl)amino)-4-(difluoromethylenyl)-1(phenylselanyl)cyclopentane-1-carboxylate (7)

Author Manuscript
Author Manuscript

To a solution of KHMDS (14.96 mL of 1M solution in THF, 14.96 mmol) and dry THF (10
mL) at −78 was added a solution of 6 (1.98 g, 6.80 mmol) in dry THF (10 mL) slowly via
syringe. The reaction mixture was stirred at −78 °C for 90 min. A solution of phenylselenyl
chloride (1.43 g, 7.48 mmol) in dry THF (2 mL) was added, and stirring was continued at
−78 °C for 75 min. The reaction mixture was then allowed to warm to 0 °C, stirred at 0 °C
for 3 h, warmed to room temperature, and stirred at room temperature for 2 h. Saturated
aqueous ammonium chloride and ethyl acetate were added, and the organic layer was
washed with saturated aqueous ammonium chloride and dried over Na2SO4. Filtration and
evaporation gave a crude mixture, which was purified by silica gel column chromatography
(hexane/EtOAc) to afford a 7:3 diastereomeric mixture (7, 2.12g, 4.75 mmol, 70%) as a pale
brown syrup; 1H NMR (500 MHz, 60 °C, DMSO-d6) δ 7.58–7.37 (m, 5H), 6.97 (s, 1H),
4.83 (s, 0.7H), 4.47 (s, 0.3H), 3.64 (s, 2.2H), 3.57 (s, 0.8H), 2.96–2.88 (m, 1H), 2.68–2.63
(m, 0.7H), 2.43–2.36 (m, 0.7H), 2.23–2.14 (m, 1.3H), 2.00–1.95 (m, 0.3H), 1.39 (s, 9H); 13C
NMR (126 MHz, DMSO-d6) δ 172.09, 171.96, 154.41, 153.76, 151.48, 150.64, 149.21,
136.79, 136.76, 129.48, 129.28, 128.91, 128.84, 126.53, 126.20, 91.00, 90.91, 90.85, 90.76,
90.70, 90.61, 77.88, 59.38, 52.11, 51.85, 51.84, 50.01, 48.64, 42.72, 40.67, 35.76, 34.17,
34.15, 27.90, 27.55.; 19F NMR (470 MHz, 60 °C, DMSO-d6) δ−88.29 (d, J = 51.2 Hz),
−89.34 (d, J = 52.9 Hz), −91.00 (d, J = 54.8 Hz).; HRMS (M+Na+) calcd for
C19H23F2NNaO4Se 470.0654, found 470.0660 (the most abundant Se isotope was selected).
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(3S)-3-((tert-Butoxycarbonyl)amino)-4-(difluoromethylenyl)-1(phenylselanyl)cyclopentane-1-carboxylic acid (8)

Author Manuscript

To a solution of 7 (1.40 g, 3.13 mmol) in methanol (14 mL) and water (4 mL) at 0 °C was
added lithium hydroxide (225 mg, 9.39 mmol). The reaction mixture was allowed to warm
to room temperature and was stirred for 20 h. Ethyl acetate was added, and the organic
solution washed with 10% citric acid and brine. The organic layer was then dried over
Na2SO4, filtered, and concentrated. The crude mixture was subjected to silica gel column
chromatography (hexane/ethyl acetate) to afford 8 (1.25 g, 2.89 mmol, 92%) as a white
powder. 1H NMR (500 MHz, 60 °C, DMSO-d6) δ 12.61 (s, 1H), 7.64–7.54 (m, 2H), 7.46–
7.42 (m, 1H), 7.41–7.35 (m, 2H), 6.94 (s, 1H), 4.81 (s, 0.7H), 4.48 (s, 0.3H), 2.97–2.83 (m,
1H), 2.67–2.56 (m, 0.7H), 2.35 (dd, J = 16.9, 2.7 Hz, 0.7H), 2.20–2.10 (m, 1.3H), 1.91 (dd, J
= 12.9, 8.3 Hz, 0.3H), 1.42–1.35 (m, 9H).; 13C NMR (126 MHz, DMSO-d6) δ 173.76,
173.56, 154.71, 154.64, 153.93, 151.65, 150.69, 149.38, 136.87, 136.81, 129.60, 129.39,
129.20, 129.14, 127.06, 126.55, 91.67, 91.52, 91.40, 91.37, 91.26, 91.11, 78.06, 52.38,
49.99, 48.69, 48.42, 42.95, 40.68, 36.08, 34.26, 28.15.; 19F NMR (470 MHz, 60 °C, DMSOd6) δ−88.52 (d, J = 52.9 Hz), −89.53 (d, J = 53.2 Hz), −91.25 (d, J = 53.2 Hz), −91.45 (d, J =
55.3 Hz).; HRMS (M+Na+) calcd for C18H21F2NNaO4Se 456.0502, found 456.0498 (the
most abundant Se isotope was selected).
(3S)-3-Amino-4-(difluoromethylenyl)-1-(phenylselanyl)cyclopentane-1-carboxylic acid (9)

Author Manuscript

To a solution of 8 (1.31 g, 3.03 mmol) in CH2Cl2 (13 mL) at 0 °C was added trifluoroacetic
acid (3.2 mL), and the reaction was stirred for 4 h at the same temperature. The mixture was
concentrated and dried in vacuo. The crude residue was subjected to cation exchange
column chromatography (Dowex 50W-X8, 5% aqueous pyridine as eluent) to afford 9 (990
mg, 2.98 mmol, 98%) as an off-white solid. 1H NMR (500 MHz, D2O) δ 7.70–7.63 (m,
2H), 7.53–7.46 (m, 1H), 7.45–7.40 (m, 2H), 4.61 (t, J = 6.7 Hz, 0.7H), 4.44 (m, 0.3H), 3.02–
2.84 (m, 1.3H), 2.71–2.57 (m, 1H), 2.49 (dd, J = 14.7, 7.8 Hz, 0.7H), 2.29 (dd, J = 14.7, 7.4
Hz, 0.7H), 2.09 (dd, J = 14.4, 5.3 Hz, 0.3H).; 13C NMR (126 MHz, D2O) δ 182.36, 181.63,
158.52, 158.05, 156.23, 155.76, 153.93, 153.46, 140.18, 139.99, 132.61, 132.55, 132.25,
132.20, 129.96, 129.65, 91.48, 91.42, 91.33, 91.26, 91.22, 91.13, 91.07, 60.00, 58.39, 52.13,
52.09, 52.03, 44.28, 43.38, 38.91, 38.30.; 19F NMR (470 MHz, D2O) δ−84.06 (d, J = 42.6
Hz), −84.38 – −84.58 (m), −84.72 (ddd, J = 45.2, 4.5, 2.4 Hz), −85.08 (ddd, J = 44.6, 5.8,
2.7 Hz).; HRMS (M+H+) calcd for C13H14F2NO2Se 334.0158, found 334.0155 (the most
abundant Se isotope was selected).
(S)-3-Amino-4-(difluoromethylenyl)cyclopent-1-ene-1-carboxylic acid Hydrochloride (5)

Author Manuscript

To a solution of 9 (100 mg, 0.30 mmol) and NaHCO3 (55 mg, 0.66 mmol) in water (2 mL)
at 0 °C was added sodium periodate (71 mg, 0.33 mmol). The reaction mixture was allowed
to warm to room temp and stirred for 6 h. The reaction mixture was directly applied to a
cation exchange column (Dowex 50W-X8, 2 N HCl as eluent) to afford a crude mixture. The
crude mixture was subjected to C-18 reverse phase column chromatography (water/
methanol) to afford a mixture of 5 and 10 (62 mg, 0.29 mmol, 96%) as a white powder
(Note: an aliquot of 2 N HCl was added when concentrating the sample to make sure the
solution was strongly acidic). To a solution of the mixture of 5 and 10 (51 mg, 0.24 mmol)
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in methanol (2 mL) and water (0.5 mL) at 0 °C was added thiosalicylic acid (112 mg, 0.72
mmol). The reaction mixture was allowed to warm to room temperature and stirred for 5 h.
After the reaction was confirmed as complete by 19F NMR spectrometry, the reaction
mixture was concentrated, and the residue was suspended in water. The suspension was
filtered through a cotton plug, and the filtrate was subjected to C-18 reverse phase column
chromatography (water/methanol) to afford 5 (23 mg, 0.11mmol, 76% from the content of 5
in the previous isomeric mixtures) as a white powder; 1H NMR (500 MHz, D2O) δ 6.29 (s,
1H), 5.16 (s, 1H), 3.37 (m, 2H).; 13C NMR (126 MHz, D2O) δ 174.42, 158.05, 155.76,
153.46, 150.08, 132.06, 89.80, 89.64, 89.59, 89.43, 57.84, 57.79, 34.85.; 19F NMR (376
MHz, D2O) δ−83.86 (ddd, J = 42.8, 6.0, 3.2 Hz), −84.12 (ddd, J = 43.0 4.9, 2.7 Hz).; HRMS
(M-H−) calcd for C7H6F2NO2 174.0372, found 174.0374.; HPLC purity (100% by UV
absorbance at 210 nm).

Author Manuscript

Analysis of Sample Purity by HPLC
An Agilent 1260 infinity HPLC system was used, which consists of a variable wavelength
detector (G1314A), a thermostatted column compartment (G1316A), an autosampler
(G1329B), an evaporative light scattering detector (ELSD, G4261A), a quaternary pump
(G1311B), and a C-18 reverse phase column (Agilent Poroshell 120, 2.7 μm, 4.6 mm × 50
mm). The experiments were run with 5 μL (0.5 mg/mL in water) injections, and sample
elution was monitored by UV absorbance at 210 nm and by ELSD in a linear gradient
experiment (water/acetonitrile with 0.05% trifluoroacetic acid, gradient system: from initial
2% acetonitrile to 100% acetonitrile in 7 min, then 100% acetonitrile for 3 min).
Enzyme and Assays

Author Manuscript

GABA-AT (1.48 mg/mL) was purified from pig brain by a procedure described previously.35
Succinic semialdehyde dehydrogenase (SSDH) was purified from GABase, a commercially
available mixture of SSDH and GABA-AT, using a known procedure. 36 GABA-AT activity
was assayed using a published method.37 GABase (Pseudomonas fluorescens) and succinic
semialdehyde were purchased from Sigma-Aldrich. The final assay solution consisted of 10
mM GABA, 1.2 mM NADP+, 5 mM α-ketoglutarate, 5 mM β-mercaptoethanol, and excess
SSDH in 50 mM potassium pyrophosphate buffer, pH 8.5. The change in UV absorbance at
340 nm at 25 °C caused by the conversion of NADP+ to NADPH was monitored. The
enzyme assays for the determination of kinact and KI values were recorded with a Shimadzu
UV-1800 UV/Vis spectrophotometer, using a 1 mm width, 10 mm path length, 45 mm height
quartz microcuvette. The enzyme assays for the GABA-AT inactivation and dialysis
experiment were recorded with a BioTek Synergy H1 microplate reader.

Author Manuscript

Determination of the kinact and KI Values
The activity of the GABA-AT was measured under the conditions described in the Enzyme
and Assays section in the presence of different concentrations of inactivators, ranging from 1
to 200 μM for 5, and from 50 to 1600 μM for CPP-115 (2). The curves of GABA-AT activity
caused by inactivation were fitted to Equation 124 using GraphPad Prism 6™ software to
afford the kobs values at each inactivator concentration.
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Equation 1

where vi is the initial velocity, vs is the steady state velocity, t is time, a0 is the initial
absorbance and kobs is the observed rate of inactivation. The kobs values were plotted against
concentrations of the compound, and the best fit curve was then fitted into Equation 224 to
afford KI and kinact values.

Equation 2

Author Manuscript

where [I] is the inactivator concentration, S is the substrate (GABA) concentration applied,
Km is the Michaelis-Menten constant of the substrate (GABA). The Km value of GABA with
GABA-AT used for the calculation was 1.3 mM.38
Inactivation of GABA-AT by 5 and CPP-115, Dialysis of the Inactivated Enzyme, and
Determination of Turnover Number

Author Manuscript

The reversibility experiment was conducted following a previously reported procedure.22 To
the GABA-AT buffer (0.443 mg/mL, 10 μL) was added 70 μL of the inactivator buffer
solution (50 mM potassium pyrophosphate, pH 8.5, 5 mM α-ketoglutarate, 5 mM βmercaptoethanol) so that the final concentration of the inactivator was 10, 40, 100, and 1000
μM (5) or 10, 100, and 1000 μM (CPP-115), and the final concentration of GABA-AT was 1
μM. A control sample was also prepared with 10 μL of the GABA-AT buffer and 70 μL
potassium pyrophosphate buffer solution. The sample solutions were incubated for 4 h at
room temperature in the dark. The remaining enzyme activity was measured by taking 5 μL
from the solution. The inactivated and the control GABA-AT solution were transferred to a
D-Tube™ Dialyzer Mini (MWCO 12–14 kDa) and dialyzed against the dialysis buffer (500
mL, 50 mM potassium pyrophosphate, pH 8.5, 0.1 mM α-ketoglutarate, 0.1 mM pyridoxal
5′-phosphate) at 4 °C. The enzyme activity was measured at 7, 24, and 48 h. The turnover
number was determined using a previously reported assay.22
Inhibition of Aspartate Aminotransferase by 5

Author Manuscript

Microtiter plate wells were loaded with 90 μL of an assay mixture containing 100 mM
potassium phosphate at pH 7.4, 5.55 mM α-ketoglutarate, 1.11 mM NADH, 5.55 mM Laspartate, 11.1 units of malic dehydrogenase, and various concentrations of 5. After
incubation of the mixture at room temperature for a few min, 10 μL of Asp-AT (3.0 units/mL
in 100 mM potassium phosphate at pH 7.4) was added. The plate was shaken at room
temperature for 1 min, and the absorbance was measured at 340 nm every 6 s for 90 min. All
assays were performed in duplicate (Supporting Information Figure S10).
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The assay was identical to that with aspartate aminotransferase except L-alanine was used as
the substrate, and lactate dehydrogenase was the enzyme in the buffer (Supporting
Information Figure S11).
Time- and Concentration- Dependent Inhibition of Ornithine Aminotransferase by 5

Author Manuscript

These assays were performed using a modification of the procedure by Juncosa, Lee, and
Silverman.39 OAT (0.25 μg) was incubated with various concentrations of 5 (0.5 μM, 2 μM,
5 μM, 10 μM, 20 μM) in 100 mM potassium pyrophosphate buffer, pH 8.0, containing 1 mM
α-ketoglutarate in a total volume of 20 μL at room temperature. At time intervals, 80 μL of
assay solution, preincubated at 37 °C for 10 min, containing PYCR1 (0.5 μg), 12.5 mM αketoglutarate, 1 mM NADH, 0.03 mM PLP, and 25 mM L-ornithine in 100 mM potassium
pyrophosphate buffer, pH 8.0, were added to the incubation mixture and assayed for OAT
activity at 37 °C for 20 min. All assays were performed in duplicate, and the remaining OAT
activity at each preincubation time at each inhibitor concentration was averaged. The natural
logarithm of the percentage of the remaining OAT activity was plotted against the
preincubation time at each inhibitor concentration to obtain the kobs (slope) value for each
concentration. The kobs is the rate constant describing the inactivation at each inhibitor
concentration. kobs is replotted against the inhibitor concentration using nonlinear regression
analysis (GraphPad Prism 6™; GraphPad Software Inc.). KI and kinact were estimated from
Equation 3,

Equation 3
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where kinact is the maximal rate of inactivation, KI is the inhibitor
concentration required for half-maximal inactivation, and [I] is the preincubation
concentration of 5 (Supporting Information Figure S12).
Inhibition of the hERG Channel
This experiment was performed by Eurofins Panlabs (Redmond, WA 98052, USA). hERG
CHO-K1 cell line was used. The test concentrations were 0.1 μM, 1 μM, and 10 μM. The
incubation time was 5 min at room temperature, cumulatively. The detection method used an
automated whole-cell patch clamp. The experiments were duplicated, and the % inhibition
of the tail current was averaged (Supporting Information Figure S13).
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Inhibition of Microsomal Cytochromes P450
These experiments were performed by Eurofins Panlabs (Redmond, WA 98052, USA).
CYP1A inhibition (HLM, phenacetin substrate), CYP2B6 inhibition (HLM, bupropion
substrate), CYP2C8 inhibition (HLM, paclitaxel substrate), CYP2C9 inhibition (HLM,
diclofenac substrate), CYP2C19 inhibition (HLM, omeprazole substrate), CYP2D6
inhibition (HLM, dextromethorphan substrate), and CYP3A inhibition (HLM, midazolam
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and testosterone substrates) were tested. The test concentration was 10 μM. The incubation
time was 10 min at 37 %. The detection method was HPLC-MS/MS. The experiments were
duplicated, and the % inhibition of the control values was averaged (Supporting Information
Figure S14).
Metabolic Stability in Human Liver Microsomes
This experiment was performed by SAI Life Sciences Ltd. (Hyderabad, India). The test
concentration of 5 was 1 μM. The incubation time was 0, 45, and 90 min at 37 %. The
detection method was by LC-MS/MS. Terfenadine was run under the same conditions as a
positive control.
MicroPET Imaging
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Adult male rats (Sprague-Dawley, 200 – 250 g, n = 16) were obtained from Taconic Farms.
Animals were maintained on a 12/12 light-dark cycle. Scanning was performed using a
Siemens Inveon. All emission scans were corrected for attenuation. Animals received
baseline microPET scans using either 11C-raclopride or 18FDG as described previously. 40
Uptake of both radiotracers occurred while animals were awake and freely moving.
Immediately prior to microPET scanning, all animals were anesthetized and maintained
under isoflurane.
Crystallization of GABA-AT with 5

Author Manuscript

GABA-AT inactivated with 5 (10 mM) was concentrated to 10 mg/mL using a 30,000
molecular weight cut off (MWCO) Amicon-Ultra centrifugal filter device (Millipore, MA),
and the concentrated protein was buffer exchanged into the crystallization buffer (40 mM
sodium acetate, pH 5.5). Crystals were grown using previously published conditions.22
Crystals with the best morphology appeared in the well solution containing 0.1 M
ammonium acetate, 0.1 M Bis-Tris pH 5.5, and 17% PEG 10000 after heterogeneous
seeding with crystals of active GABA-AT and incubation at room temperature for a week.
Crystals of GABA-AT inactivated by 5 with the best morphology were transferred into a
cryo-protecting solution (Well Solution supplemented with 25% (v/v) glycerol) before being
flash cooled in liquid nitrogen.
Data Collection and Processing

Author Manuscript

Monochromatic data sets were collected at the LS-CAT, Advanced Photon Source (APS) at
Argonne National Laboratory (ANL). Diffraction data were collected at a wavelength of
0.98 A at 100 K using a Dectris Eiger 9M. All collected data sets were indexed and
integrated using programs Autoproc41 and Aimless42. The best data set was processed at a
resolution of 1.95 A. Data collection statistics are summarized in Supporting Information
Table S2.
Structure Solution, Model Building and Refinements
The structure of GABA-AT inactivated by 5 was solved by molecular replacement using
PHASER in the Phenix software suit.43 The initial search model was based on a previously
published structure of GABA-AT (PDB Code: 1OHV). Models were rebuilt using Coot and
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refined using the program Phenix43 and analyzed using the programs Coot44 and UCSF
Chimera.45 Final refinement statistics are presented in Supporting Information Table S2
(PDB code: 6B6G). Structural figures were made using UCSF Chimera.
Construction of the Enzyme-Inhibitor Complex for MD Simulations
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Author Manuscript

A docking protocol was employed to generate the initial GABA-AT complex corresponding
to PLP bound CPP-115 and 5 for the classical MD simulation. The protein structure chosen
for this study was the X-ray crystal structure of porcine GABA-AT covalently bound to
vigabatrin (PDB ID: 1OHW) with a resolution of 2.3 A.25 The missing residues from the
beginning and the end of the dimer sequence were systematically added using UCSF
chimera interface to Modeller.46 The two covalently bound vigabatrin inhibitor molecules
were removed from the two active sites, and a PLP molecule was covalently linked to the
catalytic Lys329 residue of one of the monomers in its X-ray crystallographic pose using
UCSF chimera (preserving X-ray crystallographic hydrogen bonds). The protonation states
of the amino acid residues were determined using the H++ server. 47 The structures of nontautomerized CPP-115 and 5 corresponding to the initial complex were optimized using
Gausian09 software48 at a HF/6-31+(G) level of theory. The inhibitor and protein structures
were further refined using AutoDockTools-1.5.6 available with the MGLTools software
package.49 Refined inhibitor structures were docked into the GABA-AT active site using
Autodock 4.249 software with the Lys329 residue as a flexible sidechain. A grid box
centered on the active site was generated using Autogrid 4.2 software with a grid spacing of
0.375 A and dimensions of 45 × 45 × 45 points along the x, y, and z axes. Lamarckian
genetic algorithm (GA) was used for the conformational search with a GA population size of
150 and a maximum number of evaluations of 2,500,000. The 100 generated poses were
clustered according to their rmsd values (1.5 A cut-off), and the lowest energy conformation
of the best cluster was selected for the MD simulation of the initial complex.
Molecular Dynamics Simulations
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The inhibitor structures for initial and tautomerized complexes in this study were considered
to be in their N-protonated ketoenamine conformation.50 The electrostatic potential energies
(ESP) of the geometrically optimized inhibitors (HF/6-31+G) were calculated at the HF/
6-31+G level of theory. Then these energies were used to derive the partial atomic charges of
the inhibitors using the restricted electrostatic potential square fit (RESP) method employed
in the antechamber module available in the Amber12 program.51 This is the method used to
derive the partial atomic charges of the original Amber force fields. The inhibitor atoms
were treated with general Amber force field (GAFF), and the automatically assigned GAFF
atom types were manually adjusted to accurately represent their chemical environment
before deriving the parameters. The parameters and topology files were generated using
tLEaP and antechamber modules of the Amber12 program. Then these parameters and
topology files were converted to GROMACS compatible format using ACPYPE.52 The
force field parameters and the topology for covalently bound PLP were derived similarly.
The Amber consistent parameters (well validated) for the FeS cluster were taken from the
literature.53 The partial atomic charges and the parameters for the inhibitors and the PLP are
listed in the Supporting Information (Figures S31–S34). The modified Amber ff99SB-ILDN
force field with parameters for the FeS cluster and the covalently bound PLP were used to
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simulate the protein. Parameters for the GABA-AT dimer were derived using the pdb2gmx
module available in the GROMACS 5.1.2 software package. All of the MD simulations were
performed using GROMACS 5.1.2 software.54 The extended single point charge model
(SPC/E) was used as the water model. The catalytic Lys329 residue was treated as
deprotonated in initial and tautomerized complexes, as suggested by literature findings.55
The protein-inhibitor complex was immersed in a dodecahedron box filled with SPC/E water
where the boundaries are extending at least 1.7 nm in all directions from the edges of the
protein. Then NaCl was added to the system up to a concentration of 0.15 M (physiological
NaCl concentration) to neutralize the charge of the system. The solvated system was energy
minimized with the steepest descent followed by the conjugate gradient method until it
converged with a maximum force no greater than 500 KJmol−1nm−1. The resulting energy
minimized periodic system was the starting configuration for the MD simulation. Prior to the
production MD simulation, the system was subjected to equilibration in two steps. First, it
was equilibrated at the NVT (constant number of particles, volume, and temperature)
ensemble for 1 ns. Then the resulting system was equilibrated at the NPT (constant number
of particles, pressure, and temperature) ensemble for 5 ns. Temperature and pressure were
controlled at 310 K and 1 bar by the V-rescale thermostat (time constant of 0.4 ps) and the
Parrinello-Rahman barostat (time constant of 2 ps), respectively. In both of the equilibration
steps positions of the heavy atoms were restrained by applying a force constant of 1000
KJmol−1nm−2. After that, the position restraints were gradually reduced from 500 KJmol
−1nm−2 to 100 KJmol−1nm−2 over two runs (1 ns each). Finally, a production MD simulation
of the equilibrated system was carried out at the NPT ensemble for 50 ns (time step of 2 fs)
without positional restraints (duplicates for initial and tautomerized complexes). During the
NPT equilibration, the V-rescale thermostat was replaced by the most accurate Nose-Hoover
thermostat and used for the rest of the simulation protocol. The long-range electrostatic
interactions were treated with the particle mesh Ewald (PME) method while Coulomb and
van der Waals interactions were cut off at 1.2 nm. Bond lengths of the atoms were restrained
using the Linear Constraint Solver (LINCS) algorithm. After energy minimization the final
conformations of the inhibitor structures were isomerized in place and used as the starting
points for the next simulations (simulation of the tautomerized complex).
Catalytic Lys329-Inhibitor Distance Measurements
To determine the important distance measurements between the catalytic Lys329 nitrogen
atom and the reactive centers of the inhibitors in the tautomerized complexes, the distance
and mindist tools available in the GROMACS software package were used.
Principal Component Analysis (PCA)

Author Manuscript

Principal component analysis (PCA) was performed to study the collective motion of the
five-membered ring heavy atoms in CPP-115 and 5. A detailed procedure can be found
elsewhere. 56 Briefly, the covariance matrix (M) was constructed from the position
coordinates of the heavy atoms of the five-membered ring after all of the conformations
were least square fitted to the average structure according to Equation 4,
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Equation 4

where < > represents the mean across all time steps, and T superscript represents the trans
pose. Then this symmetric matrix was subjected to eigen decomposition to identify the
eigenvectors and corresponding eigenvalues. Each eigen vector corresponds to a specific
motion of the five-membered ring. To perform this task and the rest of the analysis, the covar
and anaeig tools available in the GROMACS software package and in-house python scripts
were utilized. The sham tool available in the GROMACS software package was used for free
energy landscape generation.
Distribution of Water Around the Catalytic Lys329 Residue
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The distribution of water molecules around the catalytic Lys329 nitrogen atom in the
tautomerized complex was examined by means of the radial distribution function (rdf). Rdf
expresses the distribution of atoms or molecules around a reference point with respect to the
bulk. The GROMACS rdf tool was used to determine the rdf.
BSSE Corrected Interaction Energy Calculations
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Theoretical calculations were performed to examine the interactions of the three tautomers
(11a, 11b, and 11c) in their X-ray crystallographic poses with the enzyme active site that
can be built into the electron density of the GABA-AT-Compound 5 X-ray crystal structure.
Interaction models were constructed by selecting the amino acid residues within a 5 A radius
from the tautomers (11a, 11b, and 11c) and placing them based on their X-ray
crystallographic distances. The amino acid residues were simplified to only their side chains,
and the PLP moiety of the tautomers was replaced with CH3 groups in their orientations
(Supporting Information Figure S8). For consistency Lys329 of all of the models was
considered to be in its protonated state. Basis set superposition error (BSSE) corrected gas
phase interaction energies of individual residues of each model were calculated using DFT
with a large B3LYP/6-311++G(d,2p) basis set (hydrogens were optimized at the same level
of theory before the calculation; atomic coordinates and energy values are given in the
Supporting Information, Tables S3-S5). The counterpoise technique was employed to
estimate the BSSE.

Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1.

Structure of (S)-3-amino-4-(difluoromethylenyl)cyclopent-1-ene-1-carboxylic acid (5)
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Figure 2.
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Classical molecular dynamics simulations of CPP-115 and 5 bound to PLP of GABA-AT.
Color legend: Yellow or orange-carbon; white-hydrogen; red-oxygen; blue-nitrogen; brownfluorine; taupe-phosphorus. (A) Distance measurements during the 50 ns of the trajectories
between the catalytic Lys329 nitrogen atom and the inhibitors after tautomerization (see
Scheme 2). The simulation of CPP-115’s tautomer stabilized after about 4 ns of simulation
as a result of a conformational change within the ring, which increased the distance between
the CF2 group and Lys329 to about 7.5A. This distance with 5 was only 4.6A (B)
Superimposition of the average equilibrated poses of CPP-115 (orange) and 5 (yellow);
average distances from the ε-nitrogen of Lys329 to the CF2 carbon atom are shown,
calculated using the last 40 ns of the trajectories.
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Figure 3.
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(A) Projection of trajectories on the common subspace defined by the top two Principal
Components (PC1 and PC2) for CPP-115 and 5 in the tautomerized complexes after
equilibration. Most of the variance is centered around only one main conformation for each
structure. (B) Free energy landscape of inhibitors along the first two PCs and average
structures corresponding to energy minima in the tautomerized complex (CPP-115 is in
orange and 5 in yellow)
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Figure 4.
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(Left) Time-dependent reactivation of inactivated GABA-AT by varying concentrations of 5
and CPP-115 after 24 h incubation with the enzyme; increasing the equivalents of 5 led to
further inactivation of the enzyme. (Right) Determination of the turnover number for 5 and
CPP-115. The remaining % enzyme activity obtained from graph A was plotted against the
equivalents of 5 used; linear regression was used on the linear portion of the curves to obtain
the X-intercept, which was the turnover number.
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Figure 5.

Structure of GABA-AT inactivated by 5. As with CPP-115, the difluoromethylene group of
5 has been hydrolyzed to a carboxylate moiety. Inactivation of the enzyme appears to be
caused by tight binding between the enzyme and a stable PLP-5 noncovalent complex, rather
than covalent modification. Color legend: PLP-5 carbons-yellow; protein carbons-white;
oxygens-red; nitrogens-blue; phosphorus-taupe. The crystal structure has been deposited in
the Protein Data Bank, PDB code 6B6G.
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Figure 6.

Radial distribution function (rdf) of water around Lys329, Lys330, and Lys207 in the
CPP-115-GABA-AT complex. A well-ordered hydration sphere can be observed around
1.8A of the terminal nitrogen atom of Lys329, whereas a more disordered one exists for all
three lysines between 2.5 and 4A.

Author Manuscript
Author Manuscript
J Am Chem Soc. Author manuscript; available in PMC 2019 February 14.

Juncosa et al.

Page 30

Author Manuscript
Author Manuscript

Figure 7.

Eight theoretical tautomers of 5-inactivated GABA-AT. 11d through 11h are irrelevant based
on crystallographic information (the indicated ring carbon is not planar); energy calculations
suggest that either 11a or 11c are the most likely tautomeric forms.
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Figure 8.

Author Manuscript

Effects of an acute dose of 5 and cocaine or nicotine on 11C-raclopride uptake in rat brain.
(Top) Basal amounts of [11C]-raclopride binding to dopamine receptors in the animal’s
brain; red indicates higher concentrations. (Middle) The increase in dopamine levels after
cocaine- or nicotine challenge displaces a significant amount of [11C]-raclopride from the
receptors. (Bottom) Administration of 5 before cocaine or nicotine administration prevents
[11C]-raclopride displacement, suggesting that dopamine levels remained constant.
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Figure 9.

Statistical parametric map images showing the effects of 5 on increased metabolic demands
in the hippocampus. (Left) Cocaine administration causes dopamine release and a strong
activation of the hippocampus, based on an increased uptake of [18F]-2′-fluoro-2′-deoxy-Dglucose (18FDG) (red color). (Right) Administration of 5 before the cocaine challenge
blocks dopamine release and prevents the activation of the hippocampus (no red color in the
hippocampus region)
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Scheme 1.

Catalytic mechanism of GABA-AT for the degradation of GABA into succinic semialdehyde
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Scheme 2.

Potential Mechanism of Inactivation of GABA-AT by CPP-115
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Scheme 3.

Synthesis of (S)-3-amino-4-(difluoromethylenyl)cyclopent-1-ene-1-carboxylic acid (5) from
CPP-115 (2).
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Basis set superimposition error-corrected gas phase interaction energies of tautomer models with individual
residues (in kcal/mol), calculated at the B3LYP/6-311++G(d,3p) level (X-ray crystallographic pose), where ++
are diffusion functions on both heavy atoms and hydrogens, d,3p are the polarization functions added to the
heavy atoms and hydrogens, 6-311 is the split valance basis set used for the calculations, and B3LYP is the
DFT method.
Residue

11a

11b

11c

Arg192

−161.88

−157.34

−167.24

Arg445

−141.41

−133.53

−141.23

Gln301

−14.28

−11.69

−17.73

Glu270

117.26

119.29

116.88

Ile72

1.09

0.28

1.27
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Lys329

−128.49

−127.97

−124.82

Phe189

−2.14

0.12

−1.67

Phe351

−6.99

−8.53

−7.55

Thr353

−2.48

−4.36

−1.94

Total

−339.32

−323.73

−344.03
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Table 2
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Effect of 5 on 11C-raclopride binding following a cocaine challenge. 5 suppressed dopamine release caused by
cocaine administration in a dose-dependent manner.
Condition

ST-CB/CBa

1

Control

3.75 ± 0.47

2

Test/retest

3.81 ± 0.33

2

3

Control/Blocked (cld rac)

0.46 ± 0.50

−88

4

Cocaine (10 mg/kg)

2.39 ± 0.21

−36

5

Cocaine/5 (0.01 mg/kg)

3.01 ± 0.44

−20

6

Cocaine/5 (0.1 mg/kg)

3.31 ± 0.52

−12

7

Cocaine/5 (1.0 mg/kg)

3.56 ± 2.11

−5

Entry

%=b

a

Author Manuscript

Striatum (dopamine-rich brain region)-Cerebellum (dopamine devoid brain region)/Cerebellum. This is to control for nonspecific binding of the
radiotracer, which in this case is very low because of its high specificity for D2 receptors.

b

Percent inhibition of cocaine-induced increase in synaptic dopamine
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